Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia
by daniel on Nov.15, 2009, under Research
Our new protocol was just listed on ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT01012830
Outlook is good, we anticipate recruitment, analysis, and publication to occur swiftly and efficiently.
HupA, an alkaloid initially identified from the Chinese herbal medicine Huperia serrata, is a potent reversible acetyl cholinesterase (AChE) inhibitor with additional unique properties including NMDA-receptor antagonist properties, neuroprotective and antioxidant effects. In animal studies, HupA was shown to possess greater inhibitory, longer-lasting, and more selective effects on AChE activity than donepezil. In clinical studies HupA improved memory, mood, and activities of daily living in patients with Alzheimer’s dementia. Adverse effects have been reported at a very low rate in all the clinical trials, and are mainly cholinergic, such as dizziness, nausea, gastrointestinal symptoms, headaches and depressed heart rate. Thus, HupA is an attractive option which may have beneficial effects not only on cognitive but also functional domains of schizophrenia.
